Treatments developed with the aim of overcoming endocrine resistance primarily in the female population, such as fulvestrant, mTOR inhibitors, and more recently CDK4/6 inhibitors and PI3K inhibitors, have also been indicated for the treatment of men with BC (26, 27, 35). The gene discussed is CDK4; the disease is breast cancer.